Skip to contentM
MBX Biosciences, Inc.
M
MBXMBX Biosciences, Inc. Released Nov 7, 2024, before the open
10-Q filed Nov 7, 2024, 38 days after period end · 0000950170-24-122840
Q3 2024 · 10-Q
Revenue—
Net Income-$18.14M-$18.14MN/M vs Q3 2023N/M vs Q2 2024 EPS Diluted-$2.78-$2.78
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MBX Biosciences, Inc. · CIK 1776111 · Engraved from SEC EDGAR
N/M vs Q2 2024
Operating Income-$19,612,000N/M Operating Cash Flowderived-$14,664,000— Free Cash Flowderived-$14,721,000— ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end
+2.0% from the close of Nov 6, 2024 to the close of Nov 7, 2024, the first after the release.
before the open$22.55$23.01 Oct 16Nov 7Nov 29